NCT06098027View on ClinicalTrials.gov

Study of [14C]CS0159 in China Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 23, 2023

Primary Completion Date

November 2, 2023

Study Completion Date

November 2, 2023

Conditions
Primary Biliary Cholangitis
Interventions
DRUG

[14C]CS0159

Single oral administration of 4mg \[14C\]CS0159

Trial Locations (1)

215006

The First Affiliated Hospital of Soochow University, Suzhou

Sponsors
All Listed Sponsors
lead

Cascade Pharmaceuticals, Inc

OTHER